SCHEMBL5451403

SCHEMBL5451403

NC(=O)c1c(N(S)C(=O)NC2CC2)sc2c1CCCC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 5/20 0.47
ALDH1A1 P00352 10/20 0.47
KDM4E B2RXH2 7/20 0.47
HPGD P15428 6/20 0.47
MAPT P10636 6/20 0.47
HSD17B10 Q99714 5/20 0.47
USP2 O75604 1/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
ALOX15 P16050 2/20 0.46
MAPK1 P28482 2/20 0.46
MDM2 Q00987 1/20 0.46
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CYP1A2 P05177 1/20 0.44
CYP2C19 P33261 1/20 0.44
RECQL P46063 1/20 0.43
TSHR P16473 3/20 0.43
MAPK10 P53779 1/20 0.43
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5448258 0.83 CFTR (0.42) FLT3ALDH1A1KDM4EHPGDMAPT
SCHEMBL5448466 0.77 GAA (0.57) FLT3ALDH1A1KDM4EHPGDMAPT
SCHEMBL5457907 0.72 MAPT (0.55) FLT3ALDH1A1KDM4EHPGDMAPT
SCHEMBL5451399 0.71 FLT3 (0.64) FLT3ALDH1A1KDM4EHPGDMAPT
SCHEMBL31502658 0.69 ALDH1A1 (0.72) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL5265532 0.68 ALDH1A1 (0.50) FLT3ALDH1A1KDM4EHPGDMAPT
SCHEMBL5456259 0.67 CFTR (0.47) ANO1
SCHEMBL5823313 0.65 ALDH1A1 (0.68) FLT3ALDH1A1KDM4EHPGDMAPT
SCHEMBL2688221 0.65 ALDH1A1 (1.00) FLT3ALDH1A1KDM4EHPGDMAPT
SCHEMBL3913986 0.65 ALDH1A1 (0.68) FLT3ALDH1A1KDM4EHPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 FLT3 3509/4885ALDH1A1 1153/4885KDM4E 3417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.